Global X China Biotech Innovation ETF
CHB was delisted on the 16th of February, 2024.
3 hedge funds and large institutions have $278K invested in Global X China Biotech Innovation ETF in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
797% more capital invested
Capital invested by funds: $31K → $278K (+$247K)
200% more funds holding
Funds holding: 1 → 3 (+2)
6.6% more ownership
Funds ownership: 0.62% → 7.22% (+6.6%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$268K |
| 2 |
BBPWM
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
|
+$4.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.85K |
CHB Hedge Fund Activity: Q4 2021 in Review
3 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Global X China Biotech Innovation ETF (CHB) for Q4 2021, worth a combined $278K — up 797% from $31K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CHB positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $268K. The largest seller was UBS Group, cutting an estimated $2.85K.
- 3 institutional investors held Global X China Biotech Innovation ETF (CHB) as of Q4 2021, up from 1 in Q3 2021.
- Funds reported $278K of Global X China Biotech Innovation ETF stock for Q4 2021, up 797% quarter-over-quarter.
- 2 funds opened new Global X China Biotech Innovation ETF positions in Q4 2021 and 0 closed out, a net change of +2 holders.
- The largest Global X China Biotech Innovation ETF buyer in Q4 2021 was Jane Street, an estimated $268K added.
- The largest Global X China Biotech Innovation ETF seller in Q4 2021 was UBS Group, an estimated $2.85K sold.
Based on aggregated 13F filings for Q4 2021.